{"id":"NCT03338621","sponsor":"Global Alliance for TB Drug Development","briefTitle":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","officialTitle":"An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-07-30","primaryCompletion":"2021-07-01","completion":"2022-06-10","firstPosted":"2017-11-09","resultsPosted":"2023-11-08","lastUpdate":"2024-03-07"},"enrollment":455,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Tuberculosis, Pulmonary","Tuberculosis, Multidrug-Resistant","Tuberculosis, MDR","Tuberculosis","Drug-Resistant Tuberculosis"],"interventions":[{"type":"DRUG","name":"Pretomanid","otherNames":["PA-824","Pa"]},{"type":"DRUG","name":"Bedaquiline","otherNames":["B","TMC207"]},{"type":"DRUG","name":"Moxifloxacin","otherNames":["M"]},{"type":"DRUG","name":"Pyrazinamide","otherNames":["Z"]},{"type":"DRUG","name":"HRZE","otherNames":["isoniazid","rifampicin","ethambutol"]},{"type":"DRUG","name":"HR","otherNames":["isoniazid","rifampicin"]}],"arms":[{"label":"Drug Sensitive BPaMZ","type":"EXPERIMENTAL"},{"label":"Drug Sensitive Standard Treatment","type":"ACTIVE_COMPARATOR"},{"label":"Drug Resistant BPaMZ","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients given BPaMZ for 17 Weeks ( or 4 months) vs. Standard HRZE/HR treatment given for 26 weeks (or 6 months) and Drug Resistant TB (DR-TB) patients given BPaMZ for 26 Weeks (or 6 months)","primaryOutcome":{"measure":"Number of Participants With Culture Negative Status by 8 Weeks","timeFrame":"Days 0-56 (8 weeks)","effectByArm":[{"arm":"Drug Sensitive-TB 2HRZE/4HR","deltaMin":70,"sd":null},{"arm":"Drug Sensitive-TB 4BPaMZ","deltaMin":122,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":16},"locations":{"siteCount":26,"countries":["Brazil","Georgia","Malaysia","Philippines","Russia","South Africa","Tanzania","Uganda"]},"refs":{"pmids":["38768617"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":150},"commonTop":["Hyperuricaemia","Arthralgia","Hyperkalaemia","Nausea","Hepatic Enzyme Increased"]}}